Kora DeBeck1, Tessa Cheng2, Julio S Montaner3, Chris Beyrer4, Richard Elliott5, Susan Sherman4, Evan Wood3, Stefan Baral6. 1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; School of Public Policy, Simon Fraser University, Vancouver, BC, Canada. 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 4. Centre for Public Health and Human Rights, Johns Hopkins School of Public Health, Baltimore, MD, USA. 5. Canadian HIV/AIDS Legal Network, Toronto, ON, Canada. 6. Centre for Public Health and Human Rights, Johns Hopkins School of Public Health, Baltimore, MD, USA. Electronic address: sbaral@jhsph.edu.
Abstract
BACKGROUND: Mounting evidence suggests that laws and policies prohibiting illegal drug use could have a central role in shaping health outcomes among people who inject drugs (PWID). To date, no systematic review has characterised the influence of laws and legal frameworks prohibiting drug use on HIV prevention and treatment. METHODS: Consistent with PRISMA guidelines, we did a systematic review of peer-reviewed scientific evidence describing the association between criminalisation of drug use and HIV prevention and treatment-related outcomes among PWID. We searched MEDLINE, Embase, SCOPUS, PsycINFO, Sociological Abstracts, CINAHL, Web of Science, and other sources. To be included in our review, a study had to meet the following eligibility criteria: be published in a peer-reviewed journal or presented as a peer-reviewed abstract at a scientific conference; examine, through any study design, the association between an a-priori set of indicators related to the criminalisation of drugs and HIV prevention or treatment among PWID; provide sufficient details on the methods followed to allow critical assessment of quality; be published or presented between Jan 1, 2006, and Dec 31, 2014; and be published in the English language. FINDINGS: We identified 106 eligible studies comprising 29 longitudinal, 49 cross-sectional, 22 qualitative, two mixed methods, four mathematical modelling studies, and no randomised controlled trials. 120 criminalisation indicators were identified (range 1-3 per study) and 150 HIV indicators were identified (1-5 per study). The most common criminalisation indicators were incarceration (n=38) and street-level policing (n=39), while the most frequent HIV prevention and treatment indicators were syringe sharing (n=35) and prevalence of HIV infection among PWID (n=28). Among the 106 studies included in this review, 85 (80%) suggested that drug criminalisation has a negative effect on HIV prevention and treatment, 10 (9%) suggested no association, five (5%) suggested a beneficial effect, one (1%) suggested both beneficial and negative effects, and five (5%) suggested both null and negative effects. INTERPRETATION: These data confirm that criminalisation of drug use has a negative effect on HIV prevention and treatment. Our results provide an objective evidence base to support numerous international policy initiatives to reform legal and policy frameworks criminalising drug use. FUNDING: Canadian Institutes of Health Research and US National Institutes of Health.
BACKGROUND: Mounting evidence suggests that laws and policies prohibiting illegal drug use could have a central role in shaping health outcomes among people who inject drugs (PWID). To date, no systematic review has characterised the influence of laws and legal frameworks prohibiting drug use on HIV prevention and treatment. METHODS: Consistent with PRISMA guidelines, we did a systematic review of peer-reviewed scientific evidence describing the association between criminalisation of drug use and HIV prevention and treatment-related outcomes among PWID. We searched MEDLINE, Embase, SCOPUS, PsycINFO, Sociological Abstracts, CINAHL, Web of Science, and other sources. To be included in our review, a study had to meet the following eligibility criteria: be published in a peer-reviewed journal or presented as a peer-reviewed abstract at a scientific conference; examine, through any study design, the association between an a-priori set of indicators related to the criminalisation of drugs and HIV prevention or treatment among PWID; provide sufficient details on the methods followed to allow critical assessment of quality; be published or presented between Jan 1, 2006, and Dec 31, 2014; and be published in the English language. FINDINGS: We identified 106 eligible studies comprising 29 longitudinal, 49 cross-sectional, 22 qualitative, two mixed methods, four mathematical modelling studies, and no randomised controlled trials. 120 criminalisation indicators were identified (range 1-3 per study) and 150 HIV indicators were identified (1-5 per study). The most common criminalisation indicators were incarceration (n=38) and street-level policing (n=39), while the most frequent HIV prevention and treatment indicators were syringe sharing (n=35) and prevalence of HIV infection among PWID (n=28). Among the 106 studies included in this review, 85 (80%) suggested that drug criminalisation has a negative effect on HIV prevention and treatment, 10 (9%) suggested no association, five (5%) suggested a beneficial effect, one (1%) suggested both beneficial and negative effects, and five (5%) suggested both null and negative effects. INTERPRETATION: These data confirm that criminalisation of drug use has a negative effect on HIV prevention and treatment. Our results provide an objective evidence base to support numerous international policy initiatives to reform legal and policy frameworks criminalising drug use. FUNDING: Canadian Institutes of Health Research and US National Institutes of Health.
Authors: Samuel R Friedman; Hannah Lf Cooper; Barbara Tempalski; Maria Keem; Risa Friedman; Peter L Flom; Don C Des Jarlais Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Josiah D Rich; Joseph W Hogan; Francis Wolf; Allison DeLong; Nickolas D Zaller; Meenakshi Mehrotra; Steven Reinert Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: P Kheirandish; S A Seyedalinaghi; M Hosseini; M R Jahani; H Shirzad; M Foroughi; M R Seyed Ahmadian; H Jabbari; M Mohraz; W McFarland Journal: J Acquir Immune Defic Syndr Date: 2010-02 Impact factor: 3.731
Authors: Robin A Pollini; Jorge Alvelais; Manuel Gallardo; Alicia Vera; Remedios Lozada; Carlos Magis-Rodriquez; Steffanie A Strathdee Journal: Drug Alcohol Depend Date: 2009-04-21 Impact factor: 4.492
Authors: Stephen W Pan; Chief Wayne M Christian; Margo E Pearce; Alden H Blair; Kate Jongbloed; Hongbin Zhang; Mary Teegee; Vicky Thomas; Martin T Schechter; Patricia M Spittal Journal: Int J Drug Policy Date: 2013-06-02
Authors: M-J S Milloy; Jane Buxton; Evan Wood; Kathy Li; Julio S G Montaner; Thomas Kerr Journal: BMC Public Health Date: 2009-05-27 Impact factor: 3.295
Authors: Linda-Gail Bekker; George Alleyne; Stefan Baral; Javier Cepeda; Demetre Daskalakis; David Dowdy; Mark Dybul; Serge Eholie; Kene Esom; Geoff Garnett; Anna Grimsrud; James Hakim; Diane Havlir; Michael T Isbell; Leigh Johnson; Adeeba Kamarulzaman; Parastu Kasaie; Michel Kazatchkine; Nduku Kilonzo; Michael Klag; Marina Klein; Sharon R Lewin; Chewe Luo; Keletso Makofane; Natasha K Martin; Kenneth Mayer; Gregorio Millett; Ntobeko Ntusi; Loyce Pace; Carey Pike; Peter Piot; Anton Pozniak; Thomas C Quinn; Jurgen Rockstroh; Jirair Ratevosian; Owen Ryan; Serra Sippel; Bruno Spire; Agnes Soucat; Ann Starrs; Steffanie A Strathdee; Nicholas Thomson; Stefano Vella; Mauro Schechter; Peter Vickerman; Brian Weir; Chris Beyrer Journal: Lancet Date: 2018-07-20 Impact factor: 79.321
Authors: Jennifer L Glick; Aimee Huang; Rienna Russo; Belinda Jivapong; Vijayasundaram Ramasamy; Lori Rosman; Danielle Pelaez; Katherine H A Footer; Susan G Sherman Journal: Drug Alcohol Depend Date: 2020-08-02 Impact factor: 4.492
Authors: Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney Journal: Lancet Date: 2019-10-23 Impact factor: 79.321